4.4 Article

Effects of glucagon-like peptide-1 receptor agonists on fracture healing in a rat osteoporotic model

Journal

EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 26, Issue 3, Pages -

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2023.12111

Keywords

fracture; glucagon-like peptide-1 receptor; liraglutide; osteoporosis

Ask authors/readers for more resources

Osteoporosis is a common disease characterized by reduced bone mass and fragility fractures, particularly among the elderly population. A study on rats with osteoporotic fractures found that treatment with GLP-1 RAs improved bone formation, inhibited osteoclast formation, and improved bone strength and mineral density. These findings suggest that GLP-1 RAs may be a novel treatment for osteoporotic fractures.
Osteoporosis is a common disease characterized by reduced bone mass, microstructural deterioration, fragility and consequent fragility fractures and is particularly prevalent among the elderly population. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on bones, their role in the prevention of osteoporotic fractures remains to be elucidated. The present study assigned female Sprague Dawley rats with osteoporotic fractures into variectomized osteoporosis (OVX), OVX + liraglutide (LIRA) (50 & mu;g/kg/day subcutaneous LIRA) and control groups. At 3 and 6 weeks postoperatively, X-ray, tartrate-resistant acid phosphatase (TRAP) staining, histological and biomechanical assays and assessment of femoral bone mineral density (BMD) were performed. Compared with the OVX group, GLP-1 RA treatment improved the formation of calluses and osseous union. TRAP staining showed significantly fewer osteoclasts in the OVX + LIRA group compared with the OVX group. In the osteoporotically fractured rats, LIRA improved bone strength at the femoral diaphysis, stiffness, ultimate load and femoral trabecular BMD Compared with the OVX group. GLP-1 RA treatment inhibited osteoclast formation and improved trabecular bone architecture and mass in osteoporotic fracture model rats, leading to improved biomechanical strength. GLP-1 RAs may be used as novel anti-osteoporotic fracture agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available